Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-APN-1607 PET Imaging in AD and Healthy Volunteers
NCT07752784Phase 3Recruiting
- Sponsor
- JYAMS PET Research & Development
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 3, open-label trial of florzolotau in Alzheimer's disease (AD) (2 arms), sponsored by JYAMS PET Research & Development. Primary endpoint: Consistency between visual interpretation results of [18F]-APN-1607 injection PET imaging and authenticity standards at 8 months. Started Aug 2026; status: recruiting.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07752784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752784.